Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina Inc. monthly Stock Chart
ILMN [NASD]
Illumina Inc.
IndexS&P 500 P/E59.82 EPS (ttm)2.78 Insider Own1.20% Shs Outstand147.74M Perf Week10.34%
Market Cap24.58B Forward P/E41.82 EPS next Y3.98 Insider Trans-9.55% Shs Float145.70M Perf Month20.91%
Income414.50M PEG3.64 EPS next Q0.73 Inst Own96.80% Short Float5.16% Perf Quarter23.23%
Sales2.25B P/S10.91 EPS this Y30.50% Inst Trans0.03% Short Ratio6.16 Perf Half Y5.32%
Book/sh13.56 P/B12.27 EPS next Y17.97% ROA11.10% Target Price153.53 Perf Year-24.00%
Cash/sh9.09 P/C18.30 EPS next 5Y16.45% ROE21.90% 52W Range127.10 - 220.86 Perf YTD-13.34%
Dividend- P/FCF52.01 EPS past 5Y28.90% ROI16.60% 52W High-24.68% Beta0.83
Dividend %- Quick Ratio3.70 Sales past 5Y19.70% Gross Margin69.70% 52W Low30.88% ATR4.87
Employees4600 Current Ratio4.30 Sales Q/Q6.20% Oper. Margin24.80% RSI (14)74.94 Volatility4.42% 2.99%
OptionableYes Debt/Eq0.51 EPS Q/Q-34.30% Profit Margin18.40% Rel Volume1.00 Prev Close166.42
ShortableYes LT Debt/Eq0.51 EarningsJul 26 AMC Payout0.00% Avg Volume1.22M Price166.35
Recom2.60 SMA2012.60% SMA5015.61% SMA2006.79% Volume1,217,134 Change-0.04%
Jul-27-16Reiterated Mizuho Neutral $138 → $148
Jul-05-16Downgrade Morgan Stanley Equal-Weight → Underweight $130 → $110
Jun-22-16Initiated CL King Buy
May-04-16Reiterated Stifel Buy $215 → $160
May-04-16Reiterated Mizuho Neutral $150 → $138
May-04-16Reiterated Canaccord Genuity Hold $160 → $140
May-03-16Reiterated UBS Buy $210 → $180
May-03-16Reiterated Morgan Stanley Overweight $140 → $130
Apr-19-16Downgrade Cantor Fitzgerald Buy → Hold
Apr-19-16Downgrade BofA/Merrill Buy → Neutral
Feb-04-16Downgrade Canaccord Genuity Buy → Hold $205 → $160
Feb-03-16Reiterated Deutsche Bank Hold $178 → $160
Jan-07-16Reiterated Barclays Equal Weight $170 → $175
Jan-07-16Initiated Deutsche Bank Hold $192
Jan-07-16Downgrade Wells Fargo Outperform → Market Perform
Dec-21-15Reiterated Stifel Buy $175 → $215
Oct-13-15Reiterated Barclays Equal Weight $215 → $170
Oct-06-15Reiterated Stifel Buy $235 → $175
Oct-06-15Reiterated Piper Jaffray Overweight $230 → $220
Oct-06-15Reiterated Leerink Partners Mkt Perform $185 → $155
Jul-29-16 07:22AM  Is It Time To Buy Illimuna Again? at Motley Fool
Jul-28-16 04:14PM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
02:23PM  Research Reports for Facebook, DuPont, Gilead & Others
01:44PM  Apples marketing guru Phil Schiller joins Illluminas board at Silicon Beat
10:10AM  Company News for July 28, 2016
09:42AM  One of Apple's most important execs just joined the board of a $25 billion genetics company
07:07AM  Illumina Lights Up After Earnings -- Here's How to Trade It Now
06:30AM  Illumina Names Philip W. Schiller to its Board of Directors Business Wire
Jul-27-16 03:56PM  Illumina soars after second-quarter results beat the Street at CNBC +8.09%
03:15PM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q2, 2016 By the Numbers : July 27, 2016
03:12PM  Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
01:55PM  Why Illumina, Goodyear, Wyndham, and 2 Other Stocks Have Traders Buzzing at Insider Monkey
01:55PM  Traders Are Watching Closely Illumina, Edwards Lifesciences & Three Other Stocks Today at Insider Monkey
09:36AM  Solid Sequencing Array Sales Help Illumina Inc. in Q2 at Motley Fool
08:29AM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition
12:35AM  Edited Transcript of ILMN earnings conference call or presentation 26-Jul-16 9:00pm GMT
Jul-26-16 05:42PM  Illumina (ILMN) Shares Climb on Q2 Earnings and Sales Beat
05:00PM  Illumina Inc Earnings Call scheduled for 5:00 pm ET today
04:21PM  Illumina tops Street 2Q forecasts
04:11PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Illumina Reports Financial Results for Second Quarter of Fiscal Year 2016 Business Wire
07:07AM  Q2 2016 Illumina Inc Earnings Release - After Market Close
Jul-25-16 12:10PM  Baron Asset Fund 2nd Quarter Letter
Jul-21-16 07:48AM  13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys
Jul-19-16 07:08AM  Illumina (ILMN) to Report Q2 Earnings: What's in the Cards?
Jul-13-16 03:26PM  Baron Funds Comments on Illumina Inc.
12:02PM  [$$] David Lee's New Fund Backs Agtech Startup at The Wall Street Journal
09:29AM  Coverage Initiated on Select Biotech Stocks
Jul-12-16 04:15PM  Exact Sciences (EXAS) Stock Rising on Illumina Takeover Speculation +6.70%
06:30AM  Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016 Business Wire
Jul-11-16 06:13PM  [$$] Lawrence Bock, Pioneering Biotech Investor, Dies at 56 at The Wall Street Journal
Jul-10-16 01:17PM  Silence the Noise: Illumina Revenue Is Trending Higher
Jul-08-16 10:27AM  Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Jul-07-16 09:20AM  Illumina Applauds FDAs Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing Business Wire
Jul-06-16 08:05PM  Obama Seeks To Make Mark On Genetic Medicine at Forbes
08:17AM  Illumina, Inc. breached its 50 day moving average in a Bearish Manner : ILMN-US : July 6, 2016
Jul-05-16 04:09PM  Illumina Downgraded On Outlook For Cancer, Academic Research
09:35AM  Stocks Make Weak Start; Tesla, Illumina Weigh
09:35AM  Illumina (ILMN) Stock Slumps on Morgan Stanley Downgrade
09:01AM  Morning Movers: Tesla Tanks on Delivery Miss; Rowan Sinks at Barrons.com
08:04AM  Analysts' Actions -- CyberArk, Nordstrom, Netflix, Skyworks and More
06:55AM  Illumina downgraded by Morgan Stanley
Jun-29-16 09:07AM  Illumina, MolecularMD to Co-Develop Oncology Diagnostics
Jun-28-16 07:29PM  Weekly CEO Sells Highlights
09:05AM  Top money managers take temperature of health stocks: 'Genomics' firms to soar at CNBC
08:00AM  Hunting for health-care winners
Jun-27-16 12:00PM  MolecularMD Enters Into a Collaboration Agreement With Illumina for Drug-Diagnostic Co-Development With Biopharma Drug Programs Marketwired
Jun-24-16 06:37PM  Steve Mandel Exits Position in Williams Companies in 1st Quarter -5.24%
08:23AM  Illumina, Inc. breached its 50 day moving average in a Bullish Manner : ILMN-US : June 24, 2016
Jun-22-16 06:00AM  Jim Cramer's Top Takeaways: Polaris, Thor, Danaher
Jun-18-16 02:00PM  10 Stocks to Buy Now From the World's Best Stock Pickers
Jun-17-16 09:14AM  Jay Flatley created a market for DNA sequencing from scratch and the result is the largest genetics company you've never heard of
Jun-16-16 09:00AM  Illumina Announces Initial Customer Orders for the Global Screening Array Business Wire
Jun-10-16 07:42AM  The Ingenious Moneymaking Method of the World's Super Investors: Buffett, Lynch, Icahn
Jun-09-16 12:00AM  Germ Sleuths Go High-Tech as Labs Get Illumina Sequencers at Bloomberg
Jun-08-16 06:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy Time Warner
Jun-07-16 07:17PM  Cramer: Uber has completely destroyed the car rental industry at CNBC
06:00AM  Illumina Announces Donald Danforth Plant Science Center to Receive Agricultural Greater Good Initiative Grant to Improve Food Security in Sub-Saharan Africa Business Wire
Jun-04-16 02:54PM  What's The Single Best $10,000 Investment To Hold For The Next 25 Years?
Jun-02-16 03:05AM  Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa Business Wire
May-31-16 06:46PM  How to Discover the Best Biotechs in the World
May-29-16 02:04PM  Are Jeff Bezos and Bill Gates Wrong About Illumina? at Motley Fool
May-26-16 04:20PM  Is Cancer the Biggest Opportunity Ahead for Illumina, Inc.? at Motley Fool
10:27AM  New Strong Sell Stocks for May 26th
May-25-16 06:30AM  Illumina to Webcast Live Presentation at Upcoming Investment Conferences in June Business Wire
May-19-16 04:11PM  ILLUMINA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-14-16 01:04PM  ILLUMINA INC Financials
May-13-16 01:26PM  Short Interest Surges In Illumina And Vertex Pharmaceuticals
May-12-16 08:28AM  Illumina: Q1 Results Hit by Soaring Costs; '16 View Down
May-11-16 12:42PM  Facebook, Google and 14 More S&P 500 Companies That Could Initiate a Dividend Soon at TheStreet
06:00AM  Inside The Brain Of Biotech's Top Venture Capitalist at Forbes
06:00AM  Biotech's Top VC Is Random, Scattered, And Could Change Everything at Forbes
May-09-16 05:58PM  ILLUMINA INC Files SEC form 10-Q, Quarterly Report
04:05PM  Illumina Registers MiSeqDx System in South Korea Business Wire
12:08PM  Weekly Large-Cap Review: Illumina Gained 4.2% for the Week
08:41AM  Collaborative Study of Whole Exome Sequencing Offers New Hope for Children with White Matter Disorders Business Wire
May-06-16 08:56AM  [$$] Illumina's Breakthroughs Could Send Stock Up 30% at Barrons.com
May-05-16 04:15PM  Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent Marketwired
11:12AM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
08:20AM  What Caused Illumina's Shares to Crash 19% In April at Motley Fool
May-04-16 12:41PM  Gene Testers Illumina, Myriad Genetics Tumble On Quarterly Earnings at Investor's Business Daily
11:07AM  Illumina (ILMN) Stock Dims After Q1 Earnings Miss, Weak 2016 Outlook at TheStreet
11:04AM  European Sales Hurt Illumina Inc. Q1 Earnings Results at Motley Fool
08:33AM  Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance Zacks
07:54AM  Early movers: TWX, PCLN, ENR, GNRC, KSS, CBS, FCAU, Z, ETSY, UA & more at CNBC
01:23AM  Edited Transcript of ILMN earnings conference call or presentation 3-May-16 9:00pm GMT Thomson Reuters StreetEvents
May-03-16 08:30PM  As Google's secretive biotech spinoff ramps up, look who it's hiring at American City Business Journals
06:00PM  Google Confirms FCA Self-Driving Pact; Illumina, CBS Report at Investor's Business Daily
05:26PM  [$$] Illumina Profit Drops Amid Climbing Expenses at The Wall Street Journal
05:00PM  Illumina Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:15PM  Illumina misses Street 1Q forecasts AP
04:09PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Illumina Reports Financial Results for First Quarter of Fiscal Year 2016 Business Wire
07:07AM  Q1 2016 Illumina Inc Earnings Release - After Market Close CCBN
Apr-30-16 12:01AM  [$$] A Healthy Prognosis for Drugs and Robots at Barrons.com
Apr-28-16 12:06PM  Why Illumina Cratered by 24% Last Week at Motley Fool
Apr-27-16 06:30AM  Illumina to Webcast Live Presentation at the Bank of America Merrill Lynch Health Care Conference Business Wire
Apr-26-16 09:05PM  Large-Cap Update: Illuminas Stock Tanks on New Earnings Estimate Market Realist
08:24AM  Does Illumina Inc.'s Slowing Growth Mean It's Time to Sell? at Motley Fool
06:25AM  One Year Later: Whatever Happened To Those Biotech Companies? at Forbes
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has a collaboration agreement With MolecularMD Corporation for drug-diagnostic co-development with biopharma drug programs. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dadswell CharlesSr VP & General CounselJul 27Sale155.008,6321,337,96040,248Jul 28 07:44 PM
FLATLEY JAY TDirectorJul 26Option Exercise36.3010,000363,000498,061Jul 28 07:39 PM
FLATLEY JAY TDirectorJul 26Sale150.0010,0001,500,000488,061Jul 28 07:39 PM
EPSTEIN ROBERT SDirectorJul 20Sale150.0030045,0007,524Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Option Exercise36.3010,000363,000498,061Jul 20 08:06 PM
EPSTEIN ROBERT SDirectorJul 18Sale150.00900135,0007,824Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Sale150.0010,0001,500,010488,061Jul 20 08:06 PM
BOWMAN A BLAINEDirectorJul 14Option Exercise42.825,000214,10020,704Jul 15 06:53 PM
BOWMAN A BLAINEDirectorJul 14Sale147.145,000735,70515,704Jul 15 06:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJul 11Sale141.89716101,59318,976Jul 12 07:47 PM
BOWMAN A BLAINEDirectorJun 16Option Exercise42.825,000214,10020,704Jun 17 07:53 PM
BOWMAN A BLAINEDirectorJun 16Sale135.085,000675,38815,704Jun 17 07:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJun 15Sale137.902,141295,24219,692Jun 15 06:47 PM
WHITFIELD ROY ADirectorJun 13Option Exercise42.822,00085,6406,653Jun 15 06:34 PM
WHITFIELD ROY ADirectorJun 13Sale140.443,800533,6722,853Jun 15 06:34 PM
EASTHAM KARINDirectorJun 01Option Exercise36.295,000181,45017,424Jun 03 07:28 PM
EASTHAM KARINDirectorJun 01Sale145.355,000726,75012,424Jun 03 07:28 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 25Sale144.732,141309,86721,833May 26 07:44 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 17Sale140.842,141301,53223,974May 19 06:56 PM
BOWMAN A BLAINEDirectorMay 12Option Exercise36.295,000181,45018,615May 13 06:03 PM
BOWMAN A BLAINEDirectorMay 12Sale137.115,000685,53513,615May 13 06:03 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 27Sale138.462,141296,44626,115Apr 28 06:34 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 18Sale176.012,141376,83528,256Apr 20 05:57 PM
Bianchi Paul LSr. VP, Human ResourcesApr 18Sale175.001,884329,70065,660Apr 20 05:33 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 13Option Exercise37.0412,500463,00042,897Apr 14 06:43 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 13Sale175.0012,5002,187,50030,397Apr 14 06:43 PM
WHITFIELD ROY ADirectorApr 12Option Exercise42.824,000171,2805,800Apr 14 06:21 PM
FLATLEY JAY TChief Executive OfficerApr 12Option Exercise36.3020,000726,000508,061Apr 14 06:42 PM
FLATLEY JAY TChief Executive OfficerApr 12Sale170.0520,0003,401,014488,061Apr 14 06:42 PM
WHITFIELD ROY ADirectorApr 12Sale170.004,000680,0001,800Apr 14 06:21 PM
WALT DAVID RDirectorApr 07Option Exercise13.304,00053,200635,840Apr 11 05:58 PM
WALT DAVID RDirectorApr 07Sale168.904,000675,596631,840Apr 11 05:58 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 05Sale166.072,141355,54630,397Apr 06 05:29 PM
Dadswell CharlesSr VP & General CounselApr 04Sale167.818,3821,406,60449,859Apr 06 05:19 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 23Sale155.052,141331,95732,538Mar 23 05:41 PM
FLATLEY JAY TChief Executive OfficerMar 22Option Exercise36.3010,000363,000498,061Mar 23 05:39 PM
FLATLEY JAY TChief Executive OfficerMar 22Sale154.1810,0001,541,759488,061Mar 23 05:39 PM
BRADBURY DANIELDirectorMar 21Option Exercise44.511,20053,41215,576Mar 22 02:51 PM
Naclerio NicholasSr VP, Corporate DevelopmentMar 21Sale154.254,520697,21030,020Mar 22 02:48 PM
BRADBURY DANIELDirectorMar 21Sale155.631,200186,75614,376Mar 22 02:51 PM
BOWMAN A BLAINEDirectorMar 17Option Exercise36.295,000181,45018,615Mar 18 08:49 PM
BOWMAN A BLAINEDirectorMar 17Sale145.245,000726,19213,615Mar 18 08:49 PM
WALT DAVID RDirectorMar 15Option Exercise13.304,00053,200635,840Mar 16 09:16 PM
WALT DAVID RDirectorMar 15Sale149.994,000599,961631,840Mar 16 09:16 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 14Sale155.915,892918,61834,679Mar 15 07:42 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 09Sale150.32871130,92955,189Mar 11 11:43 AM
FLATLEY JAY TChief Executive OfficerMar 08Option Exercise36.3010,000363,000500,915Mar 09 06:45 PM
Dadswell CharlesSr VP & General CounselMar 08Sale155.648,2661,286,51758,241Mar 09 06:38 PM
FLATLEY JAY TChief Executive OfficerMar 08Sale154.4910,0001,544,864490,915Mar 09 06:45 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 08Sale156.094,516704,90256,060Mar 09 06:52 PM
Dadswell CharlesSr VP & General CounselMar 07Sale155.0011617,98066,507Mar 09 06:38 PM
Stapley MarcEVP & Chief Administrative OfcMar 03Option Exercise0.0024,000040,801Mar 07 08:11 PM
FLATLEY JAY TChief Executive OfficerMar 03Option Exercise0.0083,8300514,614Mar 07 08:09 PM
deSouza Francis APresidentMar 03Option Exercise0.0049,2190118,880Mar 07 08:07 PM
Ronaghi MostafaSr VP & CTOMar 03Option Exercise0.0020,063062,763Mar 07 08:05 PM
ORPIN TRISTANEVP Clinical GenomicsMar 03Option Exercise0.0024,0000125,797Mar 07 08:02 PM
Naclerio NicholasSr VP, Corporate DevelopmentMar 03Option Exercise0.0020,063040,866Mar 07 08:00 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 03Option Exercise0.0024,000047,536Mar 07 07:58 PM
Dadswell CharlesSr VP & General CounselMar 03Option Exercise0.0033,750075,325Mar 07 07:56 PM
Bouchard MichelChief Accounting OfficerMar 03Option Exercise0.008,250023,746Mar 07 08:14 PM
FLATLEY JAY TChief Executive OfficerFeb 23Option Exercise36.3010,000363,000440,784Feb 25 07:05 PM
FLATLEY JAY TChief Executive OfficerFeb 23Sale152.4910,0001,524,850430,784Feb 25 07:05 PM
BRADBURY DANIELDirectorFeb 17Option Exercise44.511,70075,66716,076Feb 19 11:27 AM
BRADBURY DANIELDirectorFeb 17Sale154.741,700263,05114,376Feb 19 11:27 AM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 01Sale156.731,108173,65746,476Feb 03 06:58 PM
FLATLEY JAY TChief Executive OfficerJan 26Option Exercise36.3020,000726,000453,423Jan 28 06:09 PM
FLATLEY JAY TChief Executive OfficerJan 26Sale171.7020,0003,434,082433,423Jan 28 06:09 PM
BRADBURY DANIELDirectorJan 04Option Exercise44.511,70075,66716,076Jan 04 06:33 PM
BRADBURY DANIELDirectorJan 04Sale182.801,700310,75614,376Jan 04 06:33 PM
Dadswell CharlesSr VP & General CounselDec 28Sale188.6316831,69041,830Dec 30 02:36 PM
FLATLEY JAY TChief Executive OfficerDec 22Option Exercise31.3025,000782,550458,423Dec 24 10:54 AM
FLATLEY JAY TChief Executive OfficerDec 22Sale185.3825,0004,634,560433,423Dec 24 10:54 AM
WHITFIELD ROY ADirectorDec 14Option Exercise36.293,750136,08817,398Dec 15 05:40 PM
WHITFIELD ROY ADirectorDec 14Sale175.073,750656,51313,648Dec 15 05:40 PM
Bianchi Paul LSr. VP, Human ResourcesDec 11Sale179.9019735,44059,827Dec 14 05:48 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 11Sale179.9026046,77448,293Dec 14 05:46 PM
BRADBURY DANIELDirectorDec 10Option Exercise44.511,70075,66716,076Dec 11 06:47 PM
BRADBURY DANIELDirectorDec 10Sale182.371,700310,03714,376Dec 11 06:47 PM
EPSTEIN ROBERT SDirectorNov 27Sale185.561,000185,5606,935Nov 30 05:41 PM
Dadswell CharlesSr VP & General CounselNov 27Sale180.7216930,54240,553Nov 30 05:38 PM
FLATLEY JAY TChief Executive OfficerNov 25Option Exercise27.975,000139,850428,793Nov 27 09:52 AM
FLATLEY JAY TChief Executive OfficerNov 25Sale180.005,000900,000423,793Nov 27 09:52 AM
FLATLEY JAY TChief Executive OfficerNov 24Option Exercise27.9720,000559,400443,793Nov 25 01:56 PM
FLATLEY JAY TChief Executive OfficerNov 24Sale173.2720,0003,465,342423,793Nov 25 01:56 PM
FLATLEY JAY TChief Executive OfficerNov 16Option Exercise27.9710,000279,700433,793Nov 17 08:29 PM
FLATLEY JAY TChief Executive OfficerNov 16Sale170.0010,0001,700,000423,793Nov 17 08:29 PM
Klausner RichardSr VP, Chief Medical OfficerNov 13Sale163.52730119,37023,100Nov 16 05:16 PM
BRADBURY DANIELDirectorNov 10Option Exercise44.511,70075,66716,076Nov 12 07:42 PM
WALT DAVID RDirectorNov 10Sale154.032,000308,06436,960Nov 12 09:22 PM
BRADBURY DANIELDirectorNov 10Sale154.031,700261,84614,376Nov 12 07:42 PM
Dadswell CharlesSr VP & General CounselNov 03Sale150.0015823,70040,847Nov 04 05:44 PM
FLATLEY JAY TChief Executive OfficerOct 15Option Exercise27.9710,000279,700434,996Oct 16 09:10 PM
FLATLEY JAY TChief Executive OfficerOct 15Sale150.0010,0001,500,000424,996Oct 16 09:10 PM
BRADBURY DANIELDirectorOct 07Option Exercise44.511,70075,66716,076Oct 07 07:46 PM
BRADBURY DANIELDirectorOct 07Sale145.811,700247,87814,376Oct 07 07:46 PM
WALT DAVID RDirectorSep 29Sale171.652,000343,29438,960Oct 01 05:47 PM
Klausner RichardSr VP, Chief Medical OfficerSep 28Sale173.2042373,26424,016Sep 29 04:26 PM
Dadswell CharlesSr VP & General CounselSep 28Sale173.2015727,19241,005Sep 28 07:11 PM
FLATLEY JAY TChief Executive OfficerSep 22Option Exercise27.9725,000699,250449,996Sep 23 12:42 PM
FLATLEY JAY TChief Executive OfficerSep 22Sale192.7925,0004,819,681424,996Sep 23 12:42 PM